US Patent Issued to Regeneron Pharmaceuticals on April 1 for "Genome-based methods for reducing cardiovascular risk" (New York Inventors)

ALEXANDRIA, Va., April 2 -- United States Patent no. 12,264,366, issued on April 1, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Genome-based methods for reducing cardiovascular risk" was invented by Amy Damask (Tarrytown, N.Y.), Charles Paulding (Tarrytown, N.Y.), Aris Baras (Tarrytown, N.Y.) and Goncalo Abecasis (Tarrytown, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods of reducing cardiovascular risk by administration of a PCSK9 inhibitor to patients having a genetic profile associated with response to PCSK9 inhibitor therapy."

The patent was filed on May 16, 2020, under Application No. 16/876,030.

*For further information, including ima...